Fenofibrate, a peroxisome proliferator-activated receptor (PPAR)-α-selective agonist, is commonly used for the treatment of hypercholesterolemia and hypertriglyceridemia (Huang et al., 2008). Here, PPARA is linked to hypertriglyceridemia.